Cullinan TherapeuticsCGEM +4.70%22 PB Ratio is 3.10 as of Jun. 26, 2026, which is 138% above its 10-year median of 1.30. GuruFocus rates CGEM with a GF Score™ of 22/100. The stock has 5 warning signs investors should review. Among 1,233 Biotechnology companies, Cullinan Therapeutics ranks worse than 51.74% on this metric.
Cullinan Therapeutics Inc stock PB Ratio (=2.96) is close to 5-year high of 2.96.
The historical rank and industry rank for Cullinan Therapeutics's PB Ratio or its related term are showing as below:
CGEM'
s PB Ratio Range Over the Past 10 Years
Min: 0.61 Med: 1.3 Max: 3.84
Current: 3.1
During the past 8 years, Cullinan Therapeutics's highest PB Ratio was 3.84. The lowest was 0.61. And the median was 1.30.
CGEM's PB Ratio is ranked worse than 51.74% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs CGEM: 3.10
During the past 12 months, Cullinan Therapeutics's average Book Value Per Share Growth Rate was -36.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -16.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.20% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Cullinan Therapeutics was 30.10% per year. The lowest was -16.60% per year. And the median was 1.70% per year.
Back to Basics: PB Ratio
Cullinan Therapeutics (NAS:CGEM) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cullinan Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cullinan Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Cullinan Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Cullinan Therapeutics (CGEM) has a PB Ratio of 3.10 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cullinan Therapeutics and its competitors. This is 138% above median its historical median of 1.30. Over the past decade, Cullinan Therapeutics' PB Ratio has ranged from 0.61 to 3.84. According to the industry distribution chart, Cullinan Therapeutics ranks #638 out of 1233 companies in the Biotechnology industry, placing it in the top 51.7%.
Is Cullinan Therapeutics' PB Ratio too high?
Cullinan Therapeutics' current PB Ratio of 3.10 is 138% above median its 10-year median of 1.30. Over the past 10 years, this metric has ranged from a low of 0.61 to a high of 3.84. The Biotechnology industry median PB Ratio is 2.80. Cullinan Therapeutics' value of 3.10 is 10.7% above this industry median. Based on the distribution chart, Cullinan Therapeutics ranks #638 out of 1233 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cullinan Therapeutics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Cullinan Therapeutics' PB Ratio compare to MGTX and JBIO?
According to the Biotechnology industry distribution chart, Cullinan Therapeutics ranks #638 out of 1233 companies for PB Ratio. This places Cullinan Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.80. Cullinan Therapeutics' value of 3.10 is 10.7% above this benchmark. Historically, Cullinan Therapeutics' own PB Ratio has ranged from 0.61 to 3.84 over the past decade. While the company's 10-year median is 1.30 vs. the industry median of 2.80, Cullinan Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cullinan Therapeutics's current PB Ratio of 3.10 is 10.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cullinan Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cullinan Therapeutics's current PB Ratio is 3.10, which is 138% above median its own 10-year median of 1.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cullinan Therapeutics stock overvalued right now?
Cullinan Therapeutics (CGEM) has a current PB Ratio of 3.10. The current PB Ratio is 3.10, which is 138% above median its 10-year median of 1.30 and 10.7% above the Biotechnology industry median of 2.80. Cullinan Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cullinan Therapeutics (CGEM), the current PB Ratio is 3.10 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
22GF Score
Get the complete analysis for CGEM
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CGEM has been successfully added to your 
